Stomach cancer primary prevention

Revision as of 20:20, 14 November 2017 by Medhat (talk | contribs)
Jump to navigation Jump to search


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Stomach cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Stomach Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Endoscopy and Biopsy

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Stomach cancer primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Stomach cancer primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Stomach cancer primary prevention

CDC on Stomach cancer primary prevention

Stomach cancer primary prevention in the news

Blogs on Stomach cancer primary prevention

Directions to Hospitals Treating Stomach cancer

Risk calculators and risk factors for Stomach cancer primary prevention

Overview

Effective measures for the primary prevention of stomach cancer include smoking cessation, helicobacter pylori infection eradication, and having a balanced diet rich in fruits and vegetables.

Primary prevention

H.pylori eradication

  • Recent meta-analyses have each found that the incidence of metachronous gastric cancer following the endoscopic resection of a gastric neoplasm was reduced by the eradication of H. pylori infection ( 31–33 ).
  • Most recently, a meta-analysis comprising 24 studies (22 out of which were conducted in Asia) confirmed a lower rate of metachronous EGC following treatment of H. pylori infection; the incidence rate ratio was 0.54 (95% CI 0.46–0.65) ( 34 ).

Recommended first-line therapies for H pylori infection:

Regimen Drug dose Dosing frequency Duration(days) FDA approval
Clarithromycin triple PPI(standard or double dose

Clarithromycin(500mg)

Amoxicillin(1gm)or Metronidazole(500mg TID)

BID 14 days YES
Bismuth Quadruple PPI(standard dose)

Bismuth subcitrate (120-300mg)or Subsalicylate (300mg)

Tetracyclin(500mg)

Metronidazole(250-500mg)

BID

QID

QID

TID to QID (500mg)

10-14 days NO
Concomitant PPI (standard dose)

Clarithromycin (500mg)

Amoxicillin(1gm)

Nitroimidazole(500mg)c

BID 10 -14 days NO
Sequential PPI(standard dose)+Amoxicillin(1gm)

PPI,Clarithromycin(500mg)+Nitroimidazole(500mg)c

BID

BID

5-7 days

5-7 days

NO
Hybrid PPI(standard)+Amoxicillin(1gm)

PPI,Amoxicillin,Clarithromycin(500mg),Nitroimidazole(500mg)c

BID

BID

7 days

7 days

NO
Levofloxacin triple PPI(standard dose)

Levofloxacin(500mg)

Amoxicillin(1gm)

BID

QID

BID

10-14 days NO
Levofloxacin sequential PPI(standard or double dose)+Amoxicillin(1 gm)

PPI,Amoxicillin,Levofloxacin(500mg QD),Nitroimidazole(500mg)c

BID

BID

5-7 days NO
LOAD Levofloxacin(250mg)

PPI(double dose)

Nitazoxanide(500mg)c

Doxycycline(100mg)

QD

QD

BID

QD

7-10 days NO
: Several PPI, Clarithromycin, and Amoxicillin combinations have achieved FDA approval, PPI, Clarithromycin, Metronidazole are not an FDA approved treatment regimen.

‡: PPI, Bismuth, Tetracycline, and metronidazole prescribed separately are not an FDA approved treatment regimen. However, Pylera, a combination product containing Bismuth subcitrate, Tetracycline, Metronidazole combination with PPI for 10 days is an FDA approved regimen.

  • BID, twice daily; FDA, Food and Drug Administration; PPI, proton pump inhibitor; TID, three times daily; QD, once daily; QID, four times daily.

c:Metronidazole or Tinidazole[1]

After the failure of first-line therapy, such patients should be considered for referral for salvage treatment.

Salvage therapies for Helicobacter pylori infection
Regimen Drugs(doses) Dosing frequency Duration(days) FDA approval
Bismuth quadruple
  • PPI(standard dose)
  • Bismuth subciitrate 120-300mg or sub salicylate 300mg
  • Tetracycline 500mg
  • Metronidazole 500mg
BID

QID

QID

TID or QID

14 NO
Levofloxacin triple
  • PPI(standard dose)
  • Levofloxacin 500mg
  • Amoxicillin 1gm
BID

QD

BID

14 NO
Concomitant
  • PPI(standard dose)
  • Clarithromycin 500mg
  • Amoxicillin 1gm
  • Nitroimidazole 500mg
BID

BID

BID

BID or TID

10-14 NO
Rifabutin triple
  • PPI(standard dose)
  • Rifabutin 300mg
  • Amoxicillin 1gm
BID

QD

BID

10 NO
High-dose dual
  • PPI(standard to double dose)
  • Amoxicillin 1gm TID or 750mg QID
TID or QID

TID or QID

14 NO
  • Whenever H. pylori infection is identified and treated, testing to prove eradication should be performed using:
  • a urea breath test
  • fecal antigen test
  • biopsy-based testing at least 4 weeks after the completion of antibiotic therapy and after PPI therapy has been withheld for 1–2 weeks.

Hereditary cancer prevention

  •  Asymptomatic patients with a family history of HDGC and CDH1 mutations have a high probability of developing signet ring cell adenocarcinoma of the stomach. Prophylactic total gastrectomy is recommended for patients with family history of HDGC and CDH1mutations [11].
  • For patients with a CDH1 mutation but who are not from an HDGC family, we recommend individualized evaluation at an experienced center before prophylactic total gastrectomy is offered. [12].
  • Prophylactic gastrectomy is often advised between age 20 and 30 [12]. Some suggest timing total gastrectomy in CDH1 mutation carriers at an age that is five years younger than the youngest family member who developed gastric cancer [20,21]. Older patients are less likely to benefit from a prophylactic gastrectomy than younger patients because of a shorter life-expectancy and a higher perioperative risk.
  • patients who are older than 75 years should not undergo such a procedure, as their mortality from the procedure outweighs their mortality from gastric cancer. Decisions should be individualized based upon their comorbidities and the age of gastric cancer onset in their respective kindred. 

Gatric polyps

Polypectomy should be performed for all known neoplastic polyps and for all polyps ≥1 cm in diameter, as biopsies alone cannot exclude foci of high-grade dysplasia or early gastric cancer.

In patients with multiple polyps, the largest polyp should be excised and representative biopsies obtained from the remaining polyps.

  • Fundic gland polyps are associated with a low risk of progression to cancer.
  • Small proximal gastric polyps should be biopsied in patients with FAP to confirm their histology.
  • Large or irregular appearing polyps should be biopsied or resected completely to assess for dysplasia.
  • Low-grade dysplasia is common in fundic gland polyps, but surgery should be reserved for high-grade dysplasia or cancer [1].
  • Antral polyps are usually adenomas and should be completely resected endoscopically if possible. 

Hyperplastic polyps occur in association with H. pylori-related atrophic gastritis. They have some malignant potential. Hyperplastic polyps >0.5 cm should be resected completely. Surveillance with upper endoscopy should be performed based on the cancer risk due to concurrent chronic atrophic gastritis and other risk factors for gastric cancer.

We perform an upper endoscopy for surveillance one year after initial resection of adenomatous gastric polyps. In individuals at high risk for gastric cancer, surveillance is continued indefinitely.

For type 1 and 2 gastric neuroendocrine tumors smaller than 1 to 2 cm, endoscopic resection is the treatment of choice.

Type 3 tumors are treated by partial or total gastrectomy with local lymph node resection. 

Juvenile polyposis syndrome

  • Screening the upper gastrointestinal tract with upper endoscopy starting at the age of 12 years.
  • If polyps are detected, upper endoscopy should be repeated annually.
  • In the absence of upper gastrointestinal tract polyps, upper endoscopy can be performed every two to three years [9].

Lynch syndrome

  • Individuals with a pathogenic germline mutation in the DNA mismatch repair (MMR) or EPCAM genes have a definitive diagnosis of Lynch syndrome and should undergo screening for Lynch syndrome associated cancers. Screening recommendations for these individuals are discussed in detail below.
  • Screening for Lynch syndrome related cancers should also be considered in individuals at risk for Lynch syndrome who have either not undergone genetic evaluation or have indeterminate genetic test results.
  • extent of screening in these individuals can be individualized based on their personal and family cancer history and evidence of microsatellite instability on tumor testing. Individuals at risk for Lynch syndrome include:

Individuals in families meeting Amsterdam I or II criteria or revised Bethesda guidelines:

  • Endometrial cancer prior to age 50 years
  • First-degree relative of those with known MMR/EPCAM gene mutation
  • Individuals with >5 percent chance of a MMR gene mutation by prediction models

References

  1. "www.nature.com" (PDF).

Template:WH Template:WS